Recent Updates
Recently added Catalysts
EVO Positive Sentiment Score: 65/100

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Comment on media report Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN

Friday, November 15, 2024 1 min read
Key Takeaway: Evotec SE acknowledged receipt of a non-binding expression of interest from Halozyme Therapeutics Inc. for a potential takeover at EUR 11.00 per share. The company plans to evaluate this opportunity carefully and will inform the capital market following legal requirements. This interaction could signal strategic interest from larger firms in Evotec.

Market Sentiment Analysis

POSITIVE FACTORS

  • Evotec SE received a non-binding expression of interest for a takeover offer.
  • The offer price is set at EUR 11.00 per share, indicating potential value.
  • The company is being proactive by assessing the offer and communicating with shareholders.

Full Press Release Details

COMMENT ON MEDIA REPORT
evo_ex991.htm EXHIBIT 99.1
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
Ad hoc: Comment on media report
Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO)
With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share. The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.
- End of the ad hoc release -
Contact: Volker Braun, EVP Head of Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0) 151 1940 5058 (m), volker.braun@evotec.com

Frequently Asked Questions

What is the recent news about Evotec SE?

Evotec SE received a non-binding takeover offer from Halozyme Therapeutics for EUR 11.00 per share.

Who made an expression of interest in Evotec?

Halozyme Therapeutics Inc., a U.S. biotechnology company, expressed interest.

What steps will Evotec take regarding the takeover offer?

Evotec will analyze the offer and decide on next steps before informing the market.

How did Evotec receive the takeover offer?

The non-binding offer was received without prior contact from Halozyme.

What is the offer price from Halozyme to Evotec shareholders?

The offer price is EUR 11.00 per share for Evotec shareholders.

Tags: EVO Viatris Investor Conferences Healthcare Evotec Halozyme Therapeutics biotech takeover shareholders
Last updated: Nov 15, 2024